Company overview
Inventia Life Science develops advanced 3D cell culture and bioprinting solutions, including the RASTRUM platform, to generate reproducible, biologically relevant in vitro models for drug discovery. They offer RASTRUM Validated Solutions with predefined model blueprints for applications like pancreatic ductal adenocarcinoma and fibroblast activation, enabling decision-grade data from human-relevant 3D models. Through Inventia Discovery Services, they partner with biopharma teams to build indication-specific models in oncology, fibrosis, neurology, and immunology.
Inventia Life Science is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include 3d bioprinting, rastrum platform, cell culture models, drug discovery, biopharma services.
Products and technologies associated with Inventia Life Science include Cell Culture — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://inventialifescience.com
- Markets served
- United States & Americas
- Keywords
- 3d bioprinting, rastrum platform, cell culture models, drug discovery, biopharma services
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What 3D bioprinting platforms does Inventia Life Science offer?
- Inventia offers the RASTRUM bioprinting platform for high-throughput production of complex, multi-cellular 3D models, including RASTRUM Validated Solutions for reproducible drug response studies in tumor-stromal interactions.
- What therapeutic areas does Inventia support with their models?
- They specialize in indication-specific 3D cell models across oncology (e.g., PDAC), fibrosis, neurology, and immunology to improve preclinical study predictivity.
- Where are Inventia Life Science's locations?
- Inventia has facilities in Sydney, Australia (Alexandria and Collins Street), and Wilmington, Delaware, United States, supporting biopharma partnerships globally.
Related editorial coverage
- Drug Discovery USA 2026: What to Expect
- Lunai Bioworks and BrainStorm Therapeutics Launch AI Collaboration for Parkinson's and Rare Epilepsy
- Verge Rebrands AI Drug Discovery After Trial Setback
- Streamlined R&D at Novo Nordisk: Insights from Research Chief Petersen
- BBSW AI Solution Event: Daily Roundup
- BBSW AI Solution Event: Biotech Innovation in US
Explore lab tools and QA/QC resources for R&D teams.
